ATH alterity therapeutics limited

SRPT Duchenne Drug trial hits 5 year mark, page-3

  1. 1,847 Posts.
    lightbulb Created with Sketch. 1
    Yes when there are no safety issues and PROS like this and that about PBT2 - those are the perfect applications for an accelerated approval. Human testing with no safety issues should make the decision easy- require post approval study.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.4¢
Change
-0.001(6.67%)
Mkt cap ! $138.1M
Open High Low Value Volume
1.4¢ 1.4¢ 1.4¢ $10.85K 775.6K

Buyers (Bids)

No. Vol. Price($)
8 7479968 1.4¢
 

Sellers (Offers)

Price($) Vol. No.
1.5¢ 16767291 16
View Market Depth
Last trade - 10.10am 30/07/2025 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.